Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of
bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.